Statins, bone biology and revision arthroplasty: review of clinical and experimental evidence.
|アブストラクト||Osteoarthritis is a painful, disabling condition which is increasing in prevalence as a result of an ageing population. With no recognized disease-limiting therapeutics, arthroplasty of the hip and knee is the most common and effective treatment for lower limb osteoarthritis, however lower limb arthroplasty has a finite life-span and a proportion of patients will require revision arthroplasty. With increasing life expectancy and an increasing proportion of younger (<65 years) patients undergoing arthroplasty, the demand for revision arthroplasty after implant failure is also set to increase. Statins are cholesterol-modulating drugs widely used for cardiovascular risk reduction which have been noted to have pleiotropic effects including potentially influencing arthroplasty survival. In vitro studies have demonstrated pleiotropic effects in human bone cells, including enhancement of osteoblastogenesis following simvastatin exposure, and in vivo studies have demonstrated that intraperitoneal simvastatin can increase peri-implant bone growth in rats following titanium tibial implant insertion. There is evidence that statins may also influence osseointegration, enhancing bone growth at the bone-implant interface, subsequently improving the functional survival of implants. Data from the Danish Hip Arthroplasty Registry and the Clinical Practice Research Datalink in the UK suggest a reduction in the risk of lower limb revision arthroplasty in statin ever-users versus never-users, and a time-dependent effect of statins in reducing the risk of revision. In this article we review the clinical and experimental evidence linking statins and risk of revision arthroplasty.|
|ジャーナル名||Therapeutic advances in musculoskeletal disease|
|投稿者||Sorial, Antony K; Anjum, Sami A; Cook, Michael J; Board, Tim N; O'Neill, Terence W|
|組織名||Newcastle University, Biosciences Institute, International Centre for Life,;Newcastle upon Tyne, NE1 3BZ, UK.;Newcastle University, Newcastle upon Tyne, UK.;Centre for Epidemiology versus Arthritis, University of Manchester, Manchester,;UK.;The Centre for Hip Surgery, Wrightington, Wigan and Leigh NHS Foundation Trust,;Wigan, UK.;UK, and NIHR Manchester Biomedical Research Centre, Manchester University NHS;Foundation Trust, Manchester Academic Health Science Centre, UK.|